Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1369142 | Bioorganic & Medicinal Chemistry Letters | 2013 | 9 Pages |
A novel 2-thio-6-oxo-1,6-dihydropyrimidine-containing inhibitor of human lactate dehydrogenase (LDH) was identified by high-throughput screening (IC50 = 8.1 μM). Biochemical, surface plasmon resonance, and saturation transfer difference NMR experiments indicated that the compound specifically associated with human LDHA in a manner that required simultaneous binding of the NADH co-factor. Structural variation of the screening hit resulted in significant improvements in LDHA biochemical inhibition activity (best IC50 = 0.48 μM). A crystal structure of an optimized compound bound to human LDHA was obtained and explained many of the observed structure–activity relationships.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide